NCT03594552View on ClinicalTrials.gov

Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)

NACompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

March 12, 2020

Study Completion Date

March 12, 2020

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Arbaclofen_15

Single oral dose (15mg)

DRUG

Arbaclofen_30

Single oral dose (30mg)

DRUG

Placebo

Single oral dose placebo (oral tablet)

Trial Locations (1)

SE5 8AF

King's College London, London

All Listed Sponsors
lead

King's College London

OTHER

NCT03594552 - Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD) | Biotech Hunter | Biotech Hunter